Sivak O - Search Results

1

Efficacy of Postnatal In Vivo Nonsense Suppression Therapy in a Pax6 Mouse Model of Aniridia.

Wang X, Gregory-Evans K, Wasan KM, Sivak O, Shan X, Gregory-Evans CY. Wang X, et al. Among authors: sivak o. Mol Ther Nucleic Acids. 2017 Jun 16;7:417-428. doi: 10.1016/j.omtn.2017.05.002. Epub 2017 May 8. Mol Ther Nucleic Acids. 2017. PMID: 28624217 Free PMC article.

2

Cyclosporine A transfer between high- and low-density lipoproteins: independent from lipid transfer protein I-facilitated transfer of lipoprotein-coated phospholipids because of high affinity of cyclosporine a for the protein component of lipoproteins.

Kwong M, Sivak O, Kwong EH, Wasan KM. Kwong M, et al. Among authors: sivak o. J Pharm Sci. 2001 Sep;90(9):1308-17. doi: 10.1002/jps.1083. J Pharm Sci. 2001. PMID: 11745783

3

Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells.

Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Wasan EK, et al. Among authors: sivak o. Int J Pharm. 2002 Jul 8;241(1):57-64. doi: 10.1016/s0378-5173(02)00131-x. Int J Pharm. 2002. PMID: 12086721

4

Modifications in lipoprotein surface charge alter cyclosporine A association with low-density lipoproteins.

Wasan KM, Sivak O. Wasan KM, et al. Among authors: sivak o. Pharm Res. 2003 Jan;20(1):126-9. doi: 10.1023/a:1022215228799. Pharm Res. 2003. PMID: 12608546

5

Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.

Wasan KM, Sivak O, Cote RA, MacInnes AI, Boulanger KD, Lynn M, Christ WJ, Hawkins LD, Rossignol DP. Wasan KM, et al. Among authors: sivak o. Antimicrob Agents Chemother. 2003 Sep;47(9):2796-803. doi: 10.1128/AAC.47.9.2796-2803.2003. Antimicrob Agents Chemother. 2003. PMID: 12936976 Free PMC article.

6

Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.

Sivak O, Bartlett K, Risovic V, Choo E, Marra F, Batty DS Jr, Wasan KM. Sivak O, et al. J Pharm Sci. 2004 Jun;93(6):1382-9. doi: 10.1002/jps.20080. J Pharm Sci. 2004. PMID: 15124198

7

Determining the critical micelle concentration of a novel lipid-lowering agent, disodium ascorbyl phytostanyl phosphate (FM-VP4), using a fluorescence depolarization procedure.

Wasan KM, Choo E, Sivak O, Wallis S, Letchford K, Burt HM, Stewart DJ, Lukic T. Wasan KM, et al. Among authors: sivak o. Drug Dev Ind Pharm. 2004 Aug;30(7):725-30. doi: 10.1081/ddc-120039509. Drug Dev Ind Pharm. 2004. PMID: 15491050

8

Heat-treated Fungizone retains amphotericin B antifungal activity without renal toxicity in rats infected with Aspergillus fumigatus.

Sivak O, Bartlett K, Wasan KM. Sivak O, et al. Pharm Res. 2004 Sep;21(9):1564-6. doi: 10.1023/b:pham.0000041449.46054.b4. Pharm Res. 2004. PMID: 15497680

9

Unidirectional inhibition of lipid transfer protein I-mediated transfer of cholesteryl esters between high-density and low-density lipoproteins by amphotericin B lipid complex.

Sivak O, Lau B, Patankar N, Wasan KM. Sivak O, et al. Pharm Res. 2004 Dec;21(12):2336-9. doi: 10.1007/s11095-004-7686-2. Pharm Res. 2004. PMID: 15648266

10

Assessing lipid lowering and plasma cholesteryl ester transfer protein activity of simvastatin following administration to rabbits fed a high fat/cholesterol diet.

Risovic V, Man D, Sivak O, Lee SD, Wasan KM. Risovic V, et al. Among authors: sivak o. Drug Dev Ind Pharm. 2006 Jun;32(5):609-15. doi: 10.1080/03639040500529010. Drug Dev Ind Pharm. 2006. PMID: 16720415

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters